MILWAUKEE (Oct. 19, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is presenting atthe Midwest Regional Meeting of the American Chemical Society in Iowa City, Iowa on Wednesday, October 19, 2022.
William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix is presenting an abstract entitled, “Discovery of Selective Estrogen Receptor Beta agonists as Potential Therapeutics to Treat Hot Flashes and Memory Dysfunction in Menopausal Women.” The presentation focuses on original Estrigenix research regarding potentially safer alternatives to traditional hormone replacement therapy (HRT).
The dramatic decline in the production of estrogen during menopause can result in hot flashes, sleep disruption, memory dysfunction, anxiety, and depression in many women. While traditional HRT addresses these symptoms, it has associated risks for breast cancer and blood clots leading to stroke. For this reason, many OB/GYNs will not prescribe HRT for the 19 percent of menopausal women with a history of breast or uterine cancer or stroke.
Additionally, some women, who are not in these high-risk categories, avoid taking estrogen due to the perceived health risks.
“Traditional HRT is a double-edged sword due to the presence of two estrogen receptors, ER alpha, and ER beta. ER beta is known to control vasomotor symptoms while ER alpha is associated with the proliferation of 80 percent of breast cancer cell lines. Thus, highly selective ER beta agonists have the potential to be a safe alternative to traditional HRT,” explained Donaldson.
The American Chemical Society is one of the world’s largest scientific societies hosting scientific meetings throughout the country.
To learn more about Estrigenix and how this new therapy is helping women improve their quality of life, visit estrigenix.com.
About Estrigenix Therapeutics, Inc.
Estrigenix Therapeutics, Inc. is a Wisconsin-based, privately held pharmaceutical company leading the way in research and progress in estrogen biology. There is a known correlation between the severity of a woman’s hot flashes and her increased risk of developing dementia later in life. Estrigenix was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent hot flashes and dementia in post-menopausal women with fewer side effects than current hormone replacement therapy.
For more information and to learn how Estrigenix is pioneering the way in dementia prevention for post-menopausal women, visit estrigenix.com.
Safe Harbor Statement
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, implied and express statements regarding Estrigenix Therapeutics, Inc. plans, timelines, or presumptions of results for the Company’s lead compounds or planned development and testing. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on several assumptions concerning future events and are subject to several risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the timing, progress and results of our development efforts, the fluctuation of global economic conditions, the impact of current or future pandemics on our clinical development and regulatory review and approvals and on the manufacturing and prescribing of our lead compound, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our products for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.
Estrigenix Therapeutics is a registered trademark of Estrigenix Therapeutics, Inc.